Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity. Issue 2 (12th March 2021)

• Record Type: Journal Article
• Authors: Ashida, Shinji; Ochi, Hirofumi; Hamatani, Mio; Fujii, Chihiro; Kimura, Kimitoshi; Okada, Yoichiro; Hashi, Yuichiro; Kawamura, Kazuyuki; Ueno, Hideki; Takahashi, Ryosuke; Mizuno, Toshiki; Kondo, Takayuki
• Is Part Of: Neurology. Volume 8:Issue 2(2021)
• Publication Date: 2021-03-12
• Subjects: Neuroimmunology -- Periodicals; Neurology -- Periodicals; 616.8
• DOI: 10.1212/NXI.0000000000000945
• Languages: English
• ISSNs: 2332-7812

Abstract

Abstract : Objective: To clarify functional alterations of follicular helper T cells (Tfh) in myasthenia gravis (MG) because Tfh play important roles in helping B cells generate antibody-producing cells. Methods: A total of 24 immunotherapy-naive patients with anti–acetylcholine receptor (AchR) antibody–positive MG and 18 age-matched healthy subjects (HS) were enrolled. Samples from 6 patients were available for posttreatment analysis. Subsets of circulating Tfh (cTfh) and B cells were identified by flow cytometry analysis of surface molecules. Cytokine production by isolated cTfh subsets from 5 patients with MG and 5 HS was measured in vitro. Analysis was performed to examine the correlation between the frequency of cTfh subsets and that of plasmablasts and between cTfh subsets and the quantitative MG score. Results: cTfh increased with elevated expression of inducible T-cell costimulator (ICOS) in patients with MG. cTfh shifted to Th2 and Th17 over Th1 in MG. ICOS high cTfh produced significantly higher levels of interleukin (IL)-21, IL-4, and IL-17A than ICOS low cTfh only in patients with MG. The frequency of cTfh within CD4 T cells was more closely associated with disease severity than the serum anti-AchR antibody titer and frequency of plasmablasts within B cells. Abnormalities of cTfh were improved after immunotherapy in parallel with clinical improvement. Conclusions: Alternation of cTfh is a key feature in the development of MG and may become a biomarker for disease severity and therapeutic efficacy. Classification of Evidence: This study provides Class II evidence that the level of cTfh is associated with disease severity in patients with MG.